By 2027, we aim to cultivate more than 20 pilot capacity building platforms, serve over 200 enterprises, and incubate over 400 products ...
- Share
- Issue Time
- Dec 5,2025
Summary
From Guangdong investing 220 million yuan to build a synthetic biology pilot platform, to the intensive introduction of support policies in six provinces across the country.
At the national level, the goal of cultivating more than 20 national level platforms by 2027 has been clarified, and pilot platforms have become the core infrastructure for promoting the transition of biomanufacturing from "technological breakthroughs" to "industrial landing".
一、 Policy intensive intensification: The construction boom of building a matrix of pilot platforms for biomanufacturing from local to national levels began with precise efforts at the policy level.
As an "incubator" for industrial innovation, the pilot platform has not only been included in the focus of local industrial upgrading, but has also become a key lever for the country to promote the high-quality development of biomanufacturing.
1. Local priority: Each of the six provinces has its own focus. Guangdong Province is undoubtedly the "vanguard" in the construction of the pilot platform.
In August 2025, the Guangdong Provincial Development and Reform Commission officially approved the pilot platform project for synthetic biomanufacturing, with a total investment of 217.33 million yuan.
Focusing on the construction of four core sub platforms: intelligent microbial pilot platform (focusing on high value-added biobased products), functional macromolecule pilot platform (verifying functional protein processes), green biomass methanol pilot platform (developing biomass gasification technology), and intelligent plant pilot platform (building vertical plant factories)。
we plan to renovate 8500 square meters of site and purchase 365 sets of instruments and equipment. This is not the first layout in Guangdong.
As early as May 2024, Guangdong included the synthetic biomanufacturing pilot platform in the "Seven Provincial Pilot Platforms", and issued documents such as the "Interim Measures for the Construction and Operation Management of Pilot Platforms" in 2025, clarifying biomanufacturing as the core field.
As of now, six provinces in China, including Shanghai, Sichuan, Henan, Guizhou, and Fujian, have followed suit and formed a layout of "each with its own focus and complementary collaboration":
Shanghai: More than 360 institutions with pilot functions have been built, and a plan will be released in 2025 emphasizing the collaboration between biomanufacturing and biomedicine;
Sichuan: Focus on optimizing approval processes and talent incentives to address the pain points of slow implementation and talent shortage in pilot projects;
Zhengzhou, Henan Province: Key layout of biopharmaceutical pilot projects, targeting the blank in the biomanufacturing industry in the Central Plains region;
Guizhou: plans to achieve pilot service coverage of key industries in the province, including the field of biomanufacturing, by 2027;
Fujian: Propose to cultivate more than 30 provincial-level pilot platforms by 2028 and strengthen industry university research collaboration.
2. National Coordination: In 2027, cultivating 20 national level platforms and local practices will provide more guidance for national level planning.
In June 2025, the Ministry of Industry and Information Technology and the National Development and Reform Commission jointly issued a notice on the cultivation of pilot capacity building platforms for biomanufacturing, clarifying the goal of cultivating more than 20 pilot capacity building platforms, serving over 200 enterprises, and incubating more than 400 products by 2027.
This policy not only provides an "upgrade channel" for local platforms, but also avoids redundant construction between regions through unified standards and coordinated resources, promoting the development of pilot platforms towards "specialization, scale, and sharing".
二、 The value of the pilot platform: reducing costs for enterprises and accelerating industries
For biomanufacturing enterprises, the value of pilot platforms goes far beyond "providing venues and equipment". It connects the research and production ends and solves the core pain points of innovation implementation.
1. Lowering the threshold for entrepreneurship: From "buying equipment" to "using platforms". "In the past, starting a business required spending tens of millions of yuan to buy fermentation tanks and build production lines, but now renting a pilot platform can verify the process, reducing costs by at least 60%
The sentiment of a synthetic biology entrepreneur expresses the common needs of small and medium-sized enterprises.
The unit price of pilot equipment for biomanufacturing, such as fermentation tanks and purification systems, can easily reach millions, and it needs to be customized according to product characteristics, which is an "unbearable burden" for startups.
The sharing mode of the pilot platform allows enterprises to conduct process scale-up experiments without building their own hardware, and only need to pay service fees, significantly reducing the cost of innovation trial and error.
2. Accelerating technology transformation: Cracking the "laboratory to industry" gap.
The "parameter difference" between laboratory processes and industrial production is the biggest obstacle to the implementation of innovative biomanufacturing.
For example, if the dissolved oxygen and stirring rate parameters of a 10 liter fermentation tank in the laboratory are directly applied to a 10 ton production tank, it may result in a product yield drop of more than 50%.
The core function of the pilot platform is to optimize key process parameters, verify equipment adaptability, and provide a "replicable solution" for industrial production through "gradient amplification experiments" (such as 10L → 100L → 1000L).
Some platforms' "functional macromolecule pilot platforms" have specifically built a full process validation system from fermentation, purification to formulation for the pilot testing needs of functional proteins, which can simulate the process stability in different production scenarios - this is the ability that most research teams lack, and it is also the core concern that enterprises dare not easily put into production.
Bailun Biotechnology has profound experience in the construction of pilot platforms and has helped a large number of customers implement applications! Bioreactors are exported to 130 countries worldwide!
